Goodsurance
ES

Drug prices & Part D

Medicare's GLP-1 Weight-Loss Drug Program Is Running. Here Is Who Qualifies and a Key Cost Caveat.

The Medicare GLP-1 Bridge has been active since July 1 and covers three anti-obesity medicines at a flat monthly copay of 50 dollars, but that payment does not count toward Part D cost limits, and Extra Help subsidies do not apply to it.

By the Goodsurance editorial teamAugust 19, 2026

Correction, October 12, 2026: We first had some health rules wrong. High blood pressure counts only if it is hard to control and your BMI is 30 or more. At a BMI of 27, the conditions are prediabetes, a past heart attack or stroke, or blocked arteries in the legs or arms with symptoms. We also said a 2026 GLP-1 fill rules you out. The real rule is that you cannot use the Bridge if your Part D plan already covers a GLP-1 for you, or if you have type 2 diabetes.

The Medicare GLP-1 Bridge demonstration, launched by CMS on July 1, 2026, provides qualifying Medicare Part D enrollees access to three anti-obesity medicines at a flat monthly copay of 50 dollars. The program runs through December 31, 2027.

Medicare's GLP-1 Bridge is running, but the monthly copay of 50 dollars does not count toward your Part D cost cap and Extra Help does not apply.

The three covered drugs are Wegovy (semaglutide injection and tablets), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron tablets). CMS administers the Bridge outside the standard Part D benefit flow, using a central processor for prior authorization and pharmacy payment. A Part D plan does not need to take any action for eligible members to access Bridge drugs.

To qualify, a Part D enrollee must have a body mass index of 35 or higher; a BMI of 30 or higher with heart failure with preserved ejection fraction, hard to control high blood pressure, or chronic kidney disease stage 3a or higher; or a BMI of 27 or higher with prediabetes, a past heart attack or stroke, or peripheral artery disease with symptoms. Enrollees who already get a GLP-1 drug covered through their Part D plan are not eligible. People with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease are also not eligible for the Bridge, though their Part D plan may cover a GLP-1 for them.

Two important caveats stand out. First, the monthly copay of 50 dollars does not count toward the enrollee's Part D deductible or the annual out-of-pocket cap of 2,100 dollars for 2026. Second, the Extra Help (Low Income Subsidy) benefit cannot be applied to Bridge claims. Low-income enrollees who normally pay little or nothing for covered drugs will still owe 50 dollars per month for GLP-1 Bridge medicines. The Part D deductible does not apply to Bridge drugs.

KFF estimated roughly 3.8 million Part D enrollees met the eligibility criteria based on 2023 claims data. CMS has not announced a program to replace the Bridge after it ends in December 2027.

In plain words

Correction, October 12, 2026: We had some of the rules wrong. High blood pressure counts only if it is hard to control and your BMI is 30 or more. People with type 2 diabetes cannot use the Bridge.

Medicare started a program on July 1 to help some members get weight-loss drugs. It is called the GLP-1 Bridge. It covers three drugs: Wegovy, Zepbound (KwikPen only), and Foundayo. You pay 50 dollars a month. That payment does not count toward your yearly drug cost limit of 2,100 dollars. If you get Extra Help to lower your drug costs, that help does not apply here. You still pay 50 dollars. To qualify, your BMI must be 35 or higher. A BMI of 30 or higher can work if you have a certain type of heart failure, hard to control high blood pressure, or chronic kidney disease. A BMI of 27 or higher can work if you have prediabetes or had a heart attack or stroke. You cannot qualify if your Part D plan already covers a GLP-1 for you, or if you have type 2 diabetes. The program ends December 31, 2027, and no replacement has been announced.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026